Charles Schwab Investment Management Inc. purchased a new position in shares of Alumis Inc. (NASDAQ:ALMS - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 108,593 shares of the company's stock, valued at approximately $1,160,000. Charles Schwab Investment Management Inc. owned approximately 0.23% of Alumis as of its most recent filing with the SEC.
Other hedge funds have also added to or reduced their stakes in the company. Towerview LLC grew its position in Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company's stock valued at $4,058,000 after purchasing an additional 70,000 shares during the period. Maven Securities LTD purchased a new stake in Alumis in the second quarter worth approximately $332,000. Millennium Management LLC bought a new position in shares of Alumis in the second quarter worth approximately $3,376,000. Yu Fan purchased a new stake in shares of Alumis in the 2nd quarter worth about $10,502,000. Finally, Ally Bridge Group NY LLC purchased a new stake in Alumis in the second quarter worth $8,229,000.
Alumis Trading Down 3.5 %
Shares of NASDAQ:ALMS traded down $0.31 during trading hours on Wednesday, reaching $8.43. The stock had a trading volume of 98,527 shares, compared to its average volume of 148,498. Alumis Inc. has a 1 year low of $7.66 and a 1 year high of $13.53. The business's 50 day moving average is $10.31.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on ALMS shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research note on Thursday, November 14th. Robert W. Baird initiated coverage on Alumis in a research report on Thursday, October 31st. They issued an "outperform" rating and a $25.00 price target for the company. HC Wainwright lowered their target price on Alumis from $30.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, November 14th. Finally, Baird R W upgraded Alumis to a "strong-buy" rating in a research note on Thursday, October 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $26.83.
View Our Latest Analysis on ALMS
Alumis Company Profile
(
Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Recommended Stories
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
